PTC Therapeutics Inc at Evercore HealthCONx Conference Transcript
Okay. We're going to get started with our next panel, which I'm so excited about because it bridges some of the exciting news I've been seeing in gene therapy into some companies that are kind of hybrid, traditional biotech companies as we know them, with small molecules and biologics, but also their foray into the world of gene therapy.
Could have also [called] the panel, are you kidding me? After the Audentes acquisition for like $3 billion last night. And looking at the companies here and they're like, wait a minute, are you kidding me? Like help me understand the math here as we think about valuation.
So we have Stuart Peltz, Chief Executive Officer of PTC Therapeutics; Bradley Campbell, President and Chief Operating Officer from Amicus; and Shalini Sharp, Chief Financial Officer of Ultragenyx. And as we think about the portfolios represented here, we've actually got some exciting gene therapy efforts, some exciting traditional efforts.
So Shalini, let's start with you first. Just set the stage for us, give us a quick snapshot of Ultragenyx traditional orphan
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
